3 terminated, 1 completed. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 3, Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow AVP-786: new trials by email Literature Review of AVP-786 trials Research Report on AVP-786
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia Placebo, AVP-786 - Schizophrenia | Phase 2 / Phase 3 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 136 | 2019-02-15 | 2026-09-29 |
| Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder AVP-786, Placebo - Intermittent Explosive Disorder | Phase 2 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 10 | 2018-01-18 | 2022-05-24 |
| Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition AVP-786, Placebo - Disinhibition Syndrome | Phase 2 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | 2015-12-01 | 2026-05-13 |
| Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia AVP-786, Placebo - Schizophrenia | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 145 | 2015-09-01 | 2026-05-13 |
Schizophrenia (2) · Disruptive, Impulse Control, and Conduct Disorders (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (4)
United States (4) · Bulgaria (1) · Poland (1) · Puerto Rico (1)